Supernus Pharmaceuticals Management
Management criteria checks 3/4
Supernus Pharmaceuticals' CEO is Jack Khattar, appointed in Jan 2005, has a tenure of 20.33 years. total yearly compensation is $12.65M, comprised of 8% salary and 92% bonuses, including company stock and options. directly owns 3.6% of the company’s shares, worth $64.54M. The average tenure of the management team and the board of directors is 10.1 years and 12.8 years respectively.
Key information
Jack Khattar
Chief executive officer
US$12.6m
Total compensation
| CEO salary percentage | 7.95% |
| CEO tenure | 20.3yrs |
| CEO ownership | 3.6% |
| Management average tenure | 10.1yrs |
| Board average tenure | 12.8yrs |
Recent management updates
Recent updates
Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality
May 13
Supernus: New Direction Beckons After MDD Drug Fail (Rating Downgrade)
Apr 30Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking
Feb 10Supernus: New Approval Holds Promise Of Increased Growth
Feb 06Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
Nov 12Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk
Oct 31
Qelbree And GOCOVRI Spearhead Robust Revenue Surge, Setting The Path For Market Domination In CNS Therapeutics
Supernus Pharmaceuticals shows robust growth potential with advancements in its product pipeline and significant net sales growth from key products like Qelbree and GOCOVRI.Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives
Sep 12Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings
Aug 19Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout
Jul 02Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price
Apr 24Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
Mar 04We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt
May 10Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?
Feb 03These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well
Oct 19Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment
Oct 10Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio
Aug 19Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear
Aug 16Supernus: A Work In Progress
Jul 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | US$62m |
| Dec 31 2024 | US$13m | US$1m | US$74m |
| Sep 30 2024 | n/a | n/a | US$60m |
| Jun 30 2024 | n/a | n/a | US$5m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$13m | US$963k | US$1m |
| Sep 30 2023 | n/a | n/a | US$26m |
| Jun 30 2023 | n/a | n/a | US$43m |
| Mar 31 2023 | n/a | n/a | US$52m |
| Dec 31 2022 | US$10m | US$914k | US$61m |
| Sep 30 2022 | n/a | n/a | US$38m |
| Jun 30 2022 | n/a | n/a | US$57m |
| Mar 31 2022 | n/a | n/a | US$73m |
| Dec 31 2021 | US$8m | US$870k | US$53m |
| Sep 30 2021 | n/a | n/a | US$82m |
| Jun 30 2021 | n/a | n/a | US$100m |
| Mar 31 2021 | n/a | n/a | US$111m |
| Dec 31 2020 | US$7m | US$836k | US$127m |
| Sep 30 2020 | n/a | n/a | US$129m |
| Jun 30 2020 | n/a | n/a | US$118m |
| Mar 31 2020 | n/a | n/a | US$116m |
| Dec 31 2019 | US$8m | US$812k | US$113m |
| Sep 30 2019 | n/a | n/a | US$106m |
| Jun 30 2019 | n/a | n/a | US$105m |
| Mar 31 2019 | n/a | n/a | US$103m |
| Dec 31 2018 | US$7m | US$724k | US$111m |
Compensation vs Market: Jack's total compensation ($USD12.65M) is above average for companies of similar size in the US market ($USD6.15M).
Compensation vs Earnings: Jack's compensation has been consistent with company performance over the past year.
CEO
Jack Khattar (63 yo)
Mr. Jack A. Khattar, M.B.A., founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as Chief Executive Officer, President, Secretary and Director since 2005. He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 20.3yrs | US$12.65m | 3.6% $ 64.5m | |
| Senior VP & CFO | 3.8yrs | US$2.29m | 0.023% $ 406.3k | |
| Chief Scientific Officer & Senior VP of Intellectual Property | 13.2yrs | US$1.28m | 0.023% $ 407.0k | |
| Senior Vice President of Quality | 5.3yrs | US$1.35m | 0.027% $ 485.4k | |
| Senior VP of Research & Development and Chief Medical Officer | 5.3yrs | US$1.48m | 0.017% $ 308.7k | |
| Compliance Officer | 13.3yrs | no data | no data | |
| Senior Vice President of Marketing | 10.3yrs | no data | no data | |
| Senior Vice President of Sales | 10.3yrs | no data | no data | |
| Senior Vice President of Corporate Development | 9.8yrs | no data | no data | |
| Senior Vice President of Supply Chain | 4yrs | no data | no data |
Experienced Management: SUPN's management team is seasoned and experienced (10.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 20.3yrs | US$12.65m | 3.6% $ 64.5m | |
| Independent Chairman of the Board | 20.3yrs | US$399.69k | 0.24% $ 4.3m | |
| Independent Director | 10.2yrs | US$381.19k | 0.033% $ 598.6k | |
| Independent Director | 6.9yrs | US$368.69k | 0.040% $ 723.1k | |
| Independent Director | 15.3yrs | US$377.69k | 0.096% $ 1.7m | |
| Independent Director | 1.8yrs | US$355.19k | 0.0096% $ 172.0k |
Experienced Board: SUPN's board of directors are seasoned and experienced ( 12.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 00:11 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Supernus Pharmaceuticals, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emily Bodnar | Berenberg |
| David Buck | B. Riley Securities, Inc. |
| John Tanner | Cantor Fitzgerald & Co. |